×
News Home

Is Fate Therapeutics Inc (FATE) Stock at the Top of the Biotechnology Industry?

Friday, January 07, 2022 01:22 PM | InvestorsObserver Analysts
Is Fate Therapeutics Inc (FATE) Stock at the Top of the Biotechnology Industry?

Fate Therapeutics Inc (FATE) is near the middle in its industry group according to InvestorsObserver. FATE gets an overall rating of 36. That means it scores higher than 36 percent of stocks. Fate Therapeutics Inc gets a 41 rank in the Biotechnology industry. Biotechnology is number 94 out of 148 industries.

Overall Score - 36
FATE has an Overall Score of 36. Find out what this means to you and get the rest of the rankings on FATE!

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 36 means the stock is more attractive than 36 percent of stocks. These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Fate Therapeutics Inc Stock Today?

Fate Therapeutics Inc (FATE) stock is up 0.97% while the S&P 500 is lower by -0.12% as of 1:20 PM on Friday, Jan 7. FATE is higher by $0.48 from the previous closing price of $49.38 on volume of 509,069 shares. Over the past year the S&P 500 is higher by 23.30% while FATE is lower by -57.46%. FATE lost -$2.13 per share the over the last 12 months. Click Here to get the full Stock Report for Fate Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App